Fractyl Health, Inc. (NASDAQ:GUTS) Stock Has Average Price Target of $66.00

Fractyl Health, Inc. (NASDAQ:GUTS) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $66.00.

Several analysts have recently weighed in on GUTS shares. Weiss Ratings lowered shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Wall Street Zen downgraded Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Craig Hallum started coverage on Fractyl Health in a report on Wednesday, July 1st. They set a “buy” rating and a $48.00 price objective on the stock.

Key Headlines Impacting Fractyl Health

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: Fractyl’s investigational Revita therapy met the six-month co-primary endpoint in the ongoing REMAIN-1 pivotal study. Patients receiving Revita retained approximately 80% of their GLP-1-induced weight loss, compared with 67% for the sham-control group, a statistically significant difference with a p-value of 0.0023. The results support the company’s plans to pursue a potential FDA submission for maintaining weight loss after GLP-1 treatment is discontinued. Fractyl Health REMAIN-1 trial results
• Neutral Sentiment: The six-month findings are topline results from an ongoing pivotal study. Additional follow-up data, regulatory discussions, and a formal FDA filing will be needed before Revita can generate commercial revenue, leaving significant clinical, regulatory, and financing risks for investors.
• Negative Sentiment: Several law firms are promoting a securities class action against Fractyl and reminding investors that October 20, 2026 is the deadline to seek lead-plaintiff status. The litigation reportedly concerns allegations that Fractyl’s interim Revita data inflated its share price during two 2025 public offerings that raised approximately $76.7 million. The allegations have not been proven, but the legal overhang adds reputational, financial, and management uncertainty. Fractyl securities class action reminder

Fractyl Health Price Performance

Shares of NASDAQ:GUTS opened at $1.55 on Tuesday. Fractyl Health has a 1-year low of $1.53 and a 1-year high of $29.34. The firm has a market capitalization of $20.55 million, a PE ratio of -0.15 and a beta of 2.42. The business’s 50 day moving average is $6.89 and its 200-day moving average is $8.04. The company has a current ratio of 3.15, a quick ratio of 3.15 and a debt-to-equity ratio of 1.41.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($1.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.62) by $0.18. Sell-side analysts predict that Fractyl Health will post -6.32 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC bought a new position in Fractyl Health in the 2nd quarter worth approximately $8,968,058. Bank of America Corp DE acquired a new stake in shares of Fractyl Health in the 2nd quarter valued at $4,791,000. General Catalyst Group Management LLC bought a new stake in shares of Fractyl Health during the second quarter worth $3,880,000. Pale Fire Capital SE raised its position in shares of Fractyl Health by 84.5% during the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock worth $2,711,000 after acquiring an additional 2,711,103 shares during the last quarter. Finally, Atom Investors LP acquired a new position in shares of Fractyl Health during the fourth quarter valued at $4,143,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.